Inhibikase Therapeutics annual depreciation and amortization
2021
2022
2023
2024
2025
Inhibikase Therapeutics Depreciation & Amortization Growth & History (IKT)
Inhibikase Therapeutics's depreciation and amortization was $60,499 for fiscal 2025.
View full Inhibikase Therapeutics company overviewInhibikase Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $60,499 | $34,227 | +130.28% |
| 2024 | 2024-12-31 | $26,272 | −$151,126 | −85.19% |
| 2023 | 2023-12-31 | $177,398 | $170,675 | +2538.67% |
| 2022 | 2022-12-31 | $6,723 | $6,723 | — |
| 2021 | 2021-12-31 | $0 | — | — |
Inhibikase Therapeutics quarterly depreciation and amortization
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$24,157 | — |
| Q1 2026 | 2026-03-31 | $0 | −$12,654 | — |
| Q4 2025 | 2025-12-31 | $0 | — | — |
| Q3 2025 | 2025-09-30 | $23,688 | $17,120 | +260.66% |
| Q2 2025 | 2025-06-30 | $24,157 | $17,588 | +267.74% |
| Q1 2025 | 2025-03-31 | $12,654 | $6,086 | +92.66% |
| Q3 2024 | 2024-09-30 | $6,568 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $6,569 | −$152,635 | −95.87% |
| Q1 2024 | 2024-03-31 | $6,568 | $1,525 | +30.24% |
| Q3 2023 | 2023-09-30 | $6,568 | $4,887 | +290.72% |
| Q2 2023 | 2023-06-30 | $159,204 | $159,204 | — |
| Q1 2023 | 2023-03-31 | $5,043 | $5,043 | — |
| Q3 2022 | 2022-09-30 | $1,681 | — | — |
| Q2 2022 | 2022-06-30 | $0 | — | — |
| Q1 2022 | 2022-03-31 | $0 | — | — |
Inhibikase Therapeutics depreciation and amortization trends
Between the periods ended 2021-12-31 and 2025-12-31, Inhibikase Therapeutics's depreciation and amortization increased from $0 to $60,499, a change of $60,499. The latest reported quarter, Q2 2026, shows $0.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inhibikase Therapeutics source filings ↗